compared with the reference sUA group was 3.11 (95% CI¼1.38-7.05; p¼0.006); and after adjustment for age, gender, diabetes and cardiovascular diseases, ORs for LVH persisted significant only in the lower sUA group (OR ¼ 2.82, 95% CI ¼ 1.16-6.88, P ¼ 0.002). CONCLUSIONS: The study shows that the higher uric acid levels were associated with lower risk of all-cause mortality and left ventricular hypertrophy in the hemodialysis population. These results are in contrast to the association of hyperuricemia with higher cardiovascular risk in the general population and should be the subject of further research. 
INTRODUCTION AND AIMS:
The aim of the study was to confirm the relationship between the content of matrix proteoglycans/glycosaminoglycans assessed histologically in radial artery and circulating gastric inhibitory polypeptide (GIP), and selected markers of hemostasis, endothelial dysfunction, bone turnover and inflammation in chronic kidney disease (CKD) stage 5 patients. METHODS: The studied group consisted of 57 patients (28 hemodialyzed and 19 predialysis stage 5 CKD patients; mean age 61yrs). The examined parameters included GIP, calcium, phosphate, iPTH, fibroblast growth factor 23 (FGF-23), osteoprotegerin (OPG), osteopontin (OPN), osteocalcin (OC), secreted protein acidic and rich in cysteine (SPARC/osteonectin), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), hsCRP, interleukin-6 (IL-6), interleukin-18 (IL-18), endothelial leukocyte adhesion molecule-1 (ELAM-1/E-selectin), stromal cell-derived factor-1 alpha (SDF1a), thrombomodulin (TM), soluble necrosis factor receptor II (sTNF-R II), fibrinogen, plasminogen activator inhibitor-1 (PAI-1), transforming growth factor-b (TGF-b) and matrix metalloproteinase-2 (MMP-2).Fragments of radial artery obtained during creation of hemodialysis access were examined histologically. The sections were stained with alcian blue to demonstrate matrix proteoglycans and glycosaminoglycans and their relative content was assessed semiquantitatively (staining grades 1-3). RESULTS: Grade 3 alcian blue staining was significantly associated with higher calcium-phosphate product (p¼0.028) and with higher concentrations of hsCRP (p¼0.025), fibrinogen (p¼0.028), SDF-1a (p¼0.018), PAI-1 (p¼0.013), thrombomodulin (p¼0.037), E-selectin (0.036), and GIP (0.049). In multiple regression analysis CRP, PAI-1 and GIP predicted grade 3 alcian blue staining independently of dialysis status. GIP was the only predictor of the grade 3 alcian blue staining that was independent of CRP. CONCLUSIONS: We postulate that GIP may serve as novel risk indicator for early changes in the arterial wall as demonstrated by elevated level of matrix proteoglycans. The observed remodeling of extracellular components may then initiate processes leading to medial arterial calcification in CKD patients.
SP540 THE FGF23 -KLOTHO AXIS AND VASCULAR CACLIFICATION IN DIALYSIS PATIENTS
Efstratios Kasimatis 1 , Vaios Sigunas
INTRODUCTION AND AIMS:
The FGF23-Klotho axis is of great importance in bone endocrine function and is severely affected in dialysis patients. In these patients vascular calcification is common and contributes to their markedly increased cardiovascular morbidity. The aim of this study is to investigate the probable relationship between the FGF23-Klotho axis and the presence, extent and cardiovascular implications of vascular calcification.
METHODS:
The study included 80 patients in maintenance hemodialysis (57615 years old, dialysis vintage 64658 months). Abdominal aortic calcification was ranked using a standard semiquantitative score from 0 up to 24 in plain radiogragraphic films, while muscular arteries were evaluated in pelvis and hands films using a similar score from 0 up to 8. Extended calcification was considered if either the abdominal aortic score was 5 or the muscular arteries score 3, respectively. Soluble a-Klotho and cterm FGF23 were measured in plasma using ELISA kits. RESULTS: FGF23 levels were inversely correlated with Klotho (r¼-0.23, p¼0.04).
Abdominal aortic calcification was detected in 56 (70%) patients and was extended in 41 (51.3%) of them. Muscular arteries calcification was detected in 39 (48.8%) patients and was extended in 29 (36.3%) of them. Klotho levels were inversely correlated with both aortic (r¼-0.38, p¼0.001) and muscular arteries (r¼-0.28, p¼0.012) calcification scores, while there were no such associations regarding FGF23. In total, extended vascular calcification, in either aorta or muscular arteries, which is considered predictive of cardiovascular mortality was detected in 45 (56.3%) patients. It was correlated with traditional risk factors like age, hypertension and diabetes, as well as low Klotho levels and the latter was retained when it was controlled for FGF23 (p¼0.011). In a multivariate analysis, higher (3rd tertile vs both 1st and 2nd tertiles) Klotho levels, along with young age and normal arterial pressure, were an independent predictor of less severe vascular calcification (p¼0.025, OR¼3.91, CI: 1.19-12.89).
CONCLUSIONS:
In chronic dialysis patients, soluble Klotho but not FGF23 levels were associated with the presence and extent of vascular calcification which is a risk factor for cardiovascular events in these patients. Hypertension (HT) and heart failure (HF) are common diseases in hemodialysis patients. Antihypertensive treatment and control of blood pressure especially in this group often requires a multidrug therapy and individual approach to the patient in order to achieve proper blood pressure control before and after hemodialysis (HD).The aim of the cross-sectional, observational study was to evaluate antihypertensive treatment and HT control according to JNC, K/DOQI and ACC/AHA recommendations in the two groups of hemodialysis patients: with HF and without this diagnosis. METHODS: 86 patients hemodialyzed in Diaverum Dialysis Unit in 2016 were included into the study. The analysis of the antihypertensive treatment was based on the medical files and it consisted of a comparison of the mean blood pressure results reported during the six consecutive HD sessions. RESULTS: The both groups differed significantly in mean age, and such co-morbidities as diabetes and coronary artery disease (table 1). The mean blood pressure before HD session was 144/80 and 135/71mmHg, after HD session was 138/78 and 140/74mmHg, in HF(-) and HF(þ) groups respectively (NS). The target of blood pressure control according to recommendations after HD differed significantly between both groups (table 1) . The pattern of anti-hypertensive therapy was also different in this period of time. Percentage of patients using single, double, triple and multidrug therapy (4-6) were 12, 2, 22, 4, 30, 6, 24, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] 7, 22, 2, 30, 6, 22, 2% in HF(þ)(NS). The most often used drugs in both groups were beta-blockers, diuretics and calcium channel blockers (table 2) . CONCLUSIONS: 1. Target of blood pressure control before HD according to recommendations was achieved more often in HF(þ) patients, while post HD in HF(-) group.2. ß-blockers were significantly more often applied in the group HF(þ) patients, while calcium channel blockers in HF(-) group. 3 ß-blockers, diuretics and calcium channel blockers were the most common hypertensive drugs used in both groups. 
SP541 THE TREATMENT AND CONTROL OF HYPERTENSION IN HEMODIALYSIS PATIENTS WITH HEART FAILURE -PRELIMINARY RESULTS

Piotr
INTRODUCTION AND AIMS:
To evaluate the prognostic role of sMg on LVH and cardiac geometry in stage 5 CKD patients. METHODS: One hundred eighteen stage 5d CKD patients (60 on hemodialysis, 58 on peritoneal dialysis, 73 men) with a mean age of 62615 years were studied. Echocardiographic LVH was defined by LV mass index (LVMI) >95g/m 2 in women and >115g/m 2 in men. Based on LVMI and relative wall thickness (RWT), four LV geometric patterns were defined: normal (normal LVMI and RWT), concentric remodeling (normal LVMI and increased RWT>0.42), eccentric LVH (increased LVMI and normal RWT) and concentric LVH (increased LVMI and RWT). sMg and serum Ca (sCa) values were defined as the mean of all predialysis measurements available during the preceding 3 months.
RESULTS: Patients (n¼76) with LVH as compared to patients with no LVH (n¼42) were older in age (66614 vs. 55616 years; p<0.001), had lower sMg (2.160.3vs. 2.460.4mg/dl; p<0.001) and higher sCa (9.460.6vs. 9.160.7 mg/dl; p<0.05), malnutrition-inflammation score (5.062.8 vs. 4.062.0; p<0.05), body mass index (27.465.1 vs. 24.163.4; p<0.001), ), prevalence of diabetes (81.2 vs.18.8; p<0.05), coronary artery disease (79.4 vs.20.6; p<0.05) and peripheral vascular disease (78.3 vs. 21.7%; p<0.01). In a multivariate logistic regression analysis adjusted for all factors mentioned above, each increase of sMg by 1mg/dl was associated with 89% (OR¼ 0.11, 95% CI: 0.03-0.41; p <0.001) lower odds of having LVH.sMg was inversely associated with LVMI (r¼-0.214; p<0.05) and in a forward stepwise multivariate model (R 2 ¼ 0.209; p<0.001), sMg emerged a strong independent predictor of LVMI (p<0.01) explaining about 4% of its variance.The area under the ROC curve for predicting the development of LVH was 0.697 (p<0.001) and at an optimal sMg cutoff of 2.22 mg/dl the sensitivity and specificity of sMg in predicting the occurrence of LVH were 66 % and 69 %, respectively. Considering LV geometry, there was a progressive decrease in sMg from the normal group (2.3960.4 mg/dl) to concentric remodeling (2.3760.41mg/dl), eccentric (2.1960.31 mg/dl) and then to concentric (2.0860.36 mg/dl) group (p<0.01 for the trend) CONCLUSIONS: A lower sMg is a major determinant of echocardiographic LVH. Prospective studies may determine whether therapeutic adjustments of sMg can prevent or reduce the risk of LVH instage 5 CKD patients.
SP543 THE RELATIONSHIP BETWEEN NON-TRANSFERRIN BOUND IRON (NTBI) AND IRON UTILIZATION FOR ERYTHROPOIESIS IN MAINTENANCE HEMODIALYSIS PATIENTS
Takahiro Kuragano
INTRODUCTION AND AIMS:
The relationship between non-transferrin bound iron (NTBI) derived oxidation stress and arteriosclerosis in maintenance hemodialysis (MHD) patients has been reported. Although the administration of iron preparation induced increasing serum levels of NTBI serum levels, the factors determined NTBI or the relationship between NTBI and iron utilization for erythropoiesis has not been well established. In this study, we investigated the determinant of serum NTBI and the relationship between NTBI and iron utilization for erythropoiesis in MHD patients who had not even received the iron preparations. METHODS: Study design: multicenter cross-sectional study. We evaluated the blood levels of hemoglobin (Hb), b2-microglobulin (bMG), total cholesterol, triglyceride, iron, hepcidin, ferritin, total iron binding capacity (TIBC), NTBI, Interleukin(IL)-6, tumor necrosis factor (TNF)-a, and high sensitive (hs) CRP in 126 MHD patients who did not receive the iron preparations for the past three months. To evaluate the relationship between serum NITB and iron utilization for erythropoiesis, patients were divided into 4 groups according to Hb and ferritin levels (Hb<10 g/dL •ferritin<50 ng/ mL, Hb<10 g/dL•ferritin50 ng/mL, Hb10 g/dL•ferritin<50 ng/mL, and Hb>10 g/ dL•ferritin50 ng/mL). RESULTS: There was no significant difference in the NTBI levels in patients with or without diabetes and hepatitis C. Moreover, there was no significant correlation among NTBI, age, hemodialysis duration, and inflammation index (IL-6, TNF-a, hsCRP). In multivariate analysis, only serum ferritin was selected as a significant (b¼0.69, p<0.0001) predictor of serum NTBI levels (TSAT and total cholesterol were not selected). Even after adjusting according to the dose of ESA, the serum NTBI of patients with Hb<10 g/dL•ferritin50 ng/mL (0.726 0.5(lM Fe)) had significantly higher than any other groups ((Hb<10 g/dL•ferritin<50 ng/mL:0.5760.35 (lM Fe), Hb10 g/ dL•ferritin<50 ng/mL: 0.5860.28 (lM Fe), and Hb>10 g/dL•ferritin50 ng/ mL:0.6260.41 (lM Fe). CONCLUSIONS: In this study, we revealed that serum NTBI levels in MHD patients were related to the iron storage and iron utilization for erythropoiesis. From the present study, the patients with repleted iron storage patients and dysutilization of iron for erythropoiesis might had significantly higher serum NTBI levels, therefore iron administration to these patients may cause further increase NTBI levels which could be related to arteriosclerosis of MHD patients.
SP544 FAR INFRARED THERAPY IMPROVES ANKLE BRACHIAL INDEX IN HEMODIALYSIS PATIENTS WITH PERIPHERAL ARTERY DISEASE
Chih-Ching Lin 
